Company Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.
The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes.
In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis.
Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder.
The company was incorporated in 1987 and is based in Jupiter, Florida.
| Country | United States |
| Founded | 1987 |
| IPO Date | Nov 18, 1992 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 68 |
| CEO | Todd Davis |
Contact Details
Address: 555 Heritage Drive, Suite 200 Jupiter, Florida 33458 United States | |
| Phone | 858 550 7500 |
| Website | ligand.com |
Stock Details
| Ticker Symbol | LGND |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000886163 |
| CUSIP Number | 53220K504 |
| ISIN Number | US53220K5048 |
| Employer ID | 77-0160744 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Scott M. Plesha | Chief Executive Officer of Pelthos Therapeutics |
| Todd C. Davis Ph.D. | Director |
| Octavio Espinoza | Chief Financial Officer |
| Andrew T. Reardon J.D. | Chief Legal Officer |
| Paul J. Hadden | Senior Vice President of Investments and Business Development |
| Dr. Keith Marschke Ph.D. | Senior Vice President of Biology and Scientific Affairs |
| Dr. Vincent D. Antle Ph.D. | Senior Vice President of Technical Operations and QA - Capitsol |
| Patrick Lucy | Senior Vice President and CBO Protein Expression Business |
| Dr. Karen R. Reeves M.D. | Senior Vice President of Investments and Head of Clinical Strategy |
| Richard B. Baxter | Senior Vice President of Investment Operation |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 18, 2025 | 144 | Filing |
| Mar 4, 2025 | 144 | Filing |
| Feb 28, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 5, 2025 | SCHEDULE 13G/A | Filing |
| Dec 23, 2024 | 144 | Filing |
| Nov 27, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |